Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:12 pm EDT
Share
Lisata Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 5.26 million compared to USD 37.38 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 7.88 a year ago. Diluted loss per share from continuing operations was USD 0.65 compared to USD 7.88 a year ago.
For the nine months, net loss was USD 15.48 million compared to USD 48.24 million a year ago. Basic loss per share from continuing operations was USD 1.92 compared to USD 11.28 a year ago. Diluted loss per share from continuing operations was USD 1.92 compared to USD 11.28 a year ago.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.